TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by ...
- EMBARK for Clinical Trials (“EMBARKCT”) being developed as a scalable model of psychedelic facilitation training to support future pivotal studies - - American Medical Association (“AMA”)’s new CPT ...
“For EMBARK, we have set out to build an extraordinary training program in psychedelic-assisted psychotherapy. We don’t think a single person holds all the answers. Instead, we have gathered together ...
“As we continue to work toward our mission to revolutionize mental healthcare, we are committed to supporting the entire ecosystem. By offering a cost-free facilitator training program, we hope to ...
- EMBARK for Clinical Trials (“EMBARK CT ”) being developed as a scalable model of psychedelic facilitation training to support future pivotal studies - - American Medical Association (“AMA”)’s new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results